RxDoctor Payments Data

Anem Kohli

Neurology · Urbana, ILNPI 1295121127

Payments from drug & device makers

$1,707in general payments, 2019–2025

Across 83 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Abbott$228
  • Biohaven Pharmaceutical Holding Company Ltd.$85
  • Biohaven Pharmaceuticals, Inc.$32
  • Acadia Pharmaceuticals Inc$19
  • Teva Pharmaceuticals USA, Inc.$13
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$1,707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 60th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$38,434
Medicare patients
205
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate25$28,108
Aimovig AutoinjectorErenumab-Aooe26$24,884
UbrelvyUbrogepant23$24,706
Emgality PenGalcanezumab-Gnlm22$17,962
Ajovy AutoinjectorFremanezumab-Vfrm19$14,196
AdlarityDonepezil Hcl11$5,147
Carbamazepine ErCarbamazepine16$2,764
Levetiracetam95$2,164
Memantine Hcl117$2,142
Divalproex Sodium ErDivalproex Sodium27$2,026
Gabapentin90$1,973
Lacosamide22$1,872
Pregabalin44$1,718
Lamotrigine114$1,402
Donepezil Hcl103$855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,319$24,70623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 790 neurology providers in Illinois.

Other neurology in Urbana

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →